Skip to main content
Fig. 2 | Journal of Translational Medicine

Fig. 2

From: High lymphocyte population-related predictive factors for a long-term response in non-small cell lung cancer patients treated with pemetrexed: a retrospective observational study

Fig. 2

Transitions in blood cell counts. ad; Transitions in neutrophil (a), lymphocyte (b), monocyte (c) counts and neutrophil-to-lymphocyte ratio (d) in the peripheral blood of patients treated with Pemetrexed ± Platinum ± Bevacizumab. The mean value of lymphocyte counts is significantly higher in the long-term administration group. e–h; Transitions in neutrophil (e), lymphocyte (f), monocyte (g) counts and neutrophil-to-lymphocyte ratio (h) in the peripheral blood of patients treated with Paclitaxel + Carboplatin + Bevacizumab. There was no significant difference. NLR = neutrophil–lymphocyte ratio. Data are presented as mean ± 95%CI. *: Long-term administration vs. short-term administration; P < 0.05 (Unpaired t-test). **: Long-term administration vs. short-term administration; P < 0.01 (Unpaired t-test). †: Long-term administration vs. Intermediate-term administration; P < 0.05 (Unpaired t-test)

Back to article page